Vienna-based HealthTech scaleup XUND, which specialises in building Software as a Medical Device (SaMD), has successfully closed a €6 million pre-Series A funding round to expand across Europe, with a strategic focus on DACH and the UK.
The investment round was led by Lead Ventures and joined by J&T Ventures, with continued support from existing investors MassMutual Ventures, tba network, and LANA Ventures, who reaffirmed their commitment to XUND’s mission and growth trajectory.
Tamás Petrovics, Co-founder and CEO of XUND: “The latest investment is a testimony to the hard work of our team over the past years. It will help us accelerate our expansion across Europe while advancing the integration of our medical devices and RAVE, our cutting-edge large language model (LLM) solution. We are laying the foundation for a data-driven, personalised healthcare system that redefines how care is delivered — today and tomorrow.”
Founded in 2018 by Lukas Seper, Tamás Petrovics, and Zoltán Tarabó, XUND specialises in developing SaMD, enabling digital interactions from prevention to diagnosis. With the vision of bringing clarity to the most important decisions in healthcare, XUND’s products are already used by insurers, hospitals, and pharmaceutical companies as the first digital point of contact.
Today, the company employs more than 40 people across its locations in Vienna, Budapest, and London.
With new funding and an increasing portfolio of MDR-certified SaMD solutions, XUND is further strengthening its position as a homegrown European champion in digital health technology.
With demand for AI-powered medical devices surging across the continent, XUND believes they are well-positioned for rapid growth. Over the coming months, the company will accelerate its expansion in DACH and the UK, leveraging its MDR-certified technology to enable digital interactions from prevention to diagnosis.
“We are thrilled to partner with XUND, a company that brings clarity to the most important decisions in healthcare. Their commitment to digitising the patient journey not only enhances patient care but also streamlines operations for healthcare providers. The long-anticipated synthesis of AI technology in patient care is finally happening widely and it is truly exciting to bring down the walls between new technologies and legacy healthcare systems.
“We have immense confidence in XUND’s team and vision, and are eager to support their bold expansion efforts to transform healthcare delivery,” said Balázs Haszonics, Managing Partner at Lead Ventures.
At the same time, XUND is consolidating its role as a critical infrastructure provider in Europe’s evolving healthcare landscape — fully aligned with the EU’s latest InvestAI initiative, which plans to mobilize €200 billion for investment in AI solutions that strengthen technological sovereignty.
David Polach, Partner at J&T Ventures added: “The future of healthcare is not just digital — it’s intelligent, seamless, and deeply integrated. Our investment in XUND is driven by the thesis that AI-powered SaMD solutions will be the foundation of a more efficient, accessible, and data-driven healthcare system.
“What sets XUND apart is not only its world-class technology and the trust it has earned from some of the biggest names in healthcare but also the strength of its founding team and their bold vision. Their deep expertise, relentless execution, and commitment to transforming digital health give us full confidence that XUND is poised to become a global leader, redefining the future of healthcare at scale.”
Read the orginal article: https://www.eu-startups.com/2025/03/healthtech-startup-xund-secures-e6-million-to-strengthen-european-leadership-in-ai-powered-healthcare/
